Kisqali (Ribociclib Succinate)

Name: Kisqali
Brand: Novartis
SKU: 7583
Availability: InStock

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

Type:

Product: Kisqali Tablet

Manufacturer: Novartis

Country: Canada

Dosage: 200 mg

Qty-Price (USD):

Generic Equivalent of Kisqali

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

There is no generic product of Kisqali.

Kisqali Information

Kisqali at CanadaPharmacyOnline.com

The manufacturer of brand-name Kisqali is Novartis. It is available in many countries worldwide, including Canada.

The generic ribociclib succinate is currently unavailable (at this pharmacy).

Dosage:

Kisqali is available in the following oral strengths at this pharmacy:
• Film-coated tablets: 200 mg.

Dosage is individualized and based on your response to treatment. The starting dose for metastatic breast cancer is 600 mg once daily, while for early breast cancer, the starting dose is 400 mg once daily. Kisqali is always taken in combination with an aromatase inhibitor for early breast cancer. For metastatic breast cancer, Kisqali is always taken with an aromatase inhibitor (such as letrozole or anastrozole) or with fulvestrant.

Usage:

Kisqali (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced or metastatic breast cancer in adult women. It may be used for pre/peri-menopausal women (with ovarian suppression) and postmenopausal women as initial endocrine-based therapy or after prior endocrine therapy. It is also used to treat stage II and stage III early breast cancer at high risk of recurrence. Mechanism of Action Ribociclib selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins that drive tumor cell division. In hormone receptor-positive breast cancer, CDK4/6 activity is frequently amplified, driving cell cycle progression and cancer growth. By blocking CDK4/6, ribociclib prevents cancer cells from passing from the G1 phase (cell growth) to the S phase (DNA replication) of the cell cycle, arresting cell division and causing cancer cell death. When combined with hormone therapies (aromatase inhibitors or fulvestrant), which reduce the estrogen signals that drive HR+ cancer growth, ribociclib provides a dual attack on the tumor.

Take Kisqali exactly as your oncologist prescribes, as directed in the Product Monograph. Regular ECG and blood tests (especially liver function and blood counts) are required during treatment. Take Kisqali at the same time every day, preferably in the morning, with or without food. Swallow tablets whole. This medicine should be taken for 21 consecutive days, followed by 7 days off.

The information below summarizes some, but not all, potential side effects, risks, and interactions. Before starting Kisqali, it is essential to discuss all possible side effects, risks, and interactions with your doctor or pharmacist.

Side Effects:

The information below outlines potential side effects of Kisqali (ribociclib). It is not an exhaustive list, and individual reactions can vary.

Common side effects: These are common side effects of Kisqali; other side effects are possible. Contact your doctor promptly if any side effects are persistent, worsening, or concerning.
• Decreased white blood cell count (neutropenia)
• Fatigue or weakness
• Hair thinning or hair loss
• Nausea, diarrhea, or vomiting
• Skin rash

Serious Side Effects: Seek immediate medical attention or call emergency services if you experience any of the following symptoms:
• Liver Toxicity (Hepatotoxicity): Jaundice, dark urine, right upper abdominal pain, or extreme fatigue. Liver function tests are monitored regularly.
• QT Interval Prolongation (Cardiac Rhythm Abnormality): Dizziness, fainting, or palpitations. Kisqali can prolong the QT interval on ECG, which can cause potentially fatal heart rhythm abnormalities. An ECG is required before starting treatment, and regular ECG monitoring is performed during therapy. Drugs that also prolong QT must be avoided.
• Severe Allergic Reaction: Hives, swelling of the face, lips, tongue, or throat, or difficulty breathing.
• Severe Neutropenia (Very Low White Blood Cells): Fever, chills, or signs of serious infection. Kisqali commonly causes low white blood cell counts; severe neutropenia requiring dose reduction or treatment interruption occurs in some patients.

Contraindications:

Do not take Kisqali/ribociclib if:
• Allergies: Known hypersensitivity to ribociclib or any ingredient in the tablet.
• Pre-existing QT prolongation or risk factors for QT prolongation: Certain heart conditions or concurrent use of drugs that prolong QT.

Tell your doctor about all of your medical conditions, past and present, before starting Kisqali. This is crucial as certain conditions affect the drug's safety.
• Electrolyte abnormalities
• Heart conditions
• Liver disease

Drug Interactions:

Before taking Kisqali, discuss all potential risks and interactions with your doctor or pharmacist. For complete information, please refer to the product monograph at https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf.

Provide your doctor with a complete list of all your medications, including prescriptions, over-the-counter (OTC) drugs, vitamins, herbal supplements, recreational drugs, and any significant dietary changes, as these may interact with Kisqali. Kisqali may interact with other medicines, including but not limited to:
• CYP3A4 inducers (e.g., rifampicin, St. John's Wort): Significantly reduce ribociclib levels; avoid.
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, grapefruit juice): Significantly increase ribociclib exposure; avoid concurrent use. Avoid grapefruit juice.
• Drugs that prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, antibiotics) must be avoided during Kisqali treatment due to increased risk of fatal arrhythmias.

Pregnancy and Breastfeeding:

Inform your doctor if you are pregnant or planning to become pregnant. Kisqali can cause harm to an unborn baby. Women of childbearing potential must use effective non-hormonal contraception during treatment and for at least 3 weeks after the final dose. Kisqali must not be used during pregnancy. Consult your doctor to weigh the benefits and risks of this medicine before using it while nursing. Breastfeeding must be discontinued while taking Kisqali and for at least 3 weeks after the final dose.

Use in Children:

The safety and efficacy of Kisqali in patients under 18 years of age have not been established. It is not recommended for use in children.

Frequently Asked Questions about Kisqali at Canada Pharmacy Online

Why is Kisqali more affordable in Canada than in the United States?

Prescription drug prices, including Kisqali, are generally lower in Canada than in the U.S. due to a combination of factors, primarily government price regulations, differing market dynamics, and other economic considerations. In Canada, provincial and federal governments negotiate drug prices with pharmaceutical companies, which often results in lower prices than in the U.S., where market forces play a more significant role. For more information, see the FAQs on Prescription Drug Importation from the Kaiser Family Foundation (KFF): https://www.kff.org/health-costs/issue-brief/faqs-on-prescription-drug-importation/

How much is the shipping?

Our shipping fee is a flat rate of $10.00 per order. Our pharmacy is dedicated to offering you the lowest prices on high-quality products.

How do I place an order with your pharmacy?

Ordering from us is very simple. You can purchase online or call Customer Service at 1.866.920.3784; for more information or to learn about the ordering process, visit our How to Order page.

Is there a limit on how many Kisqali I can order at once?

CanadaPharmacyOnline.com can dispense up to a three-month supply of Kisqali per prescription from your doctor.

Can I buy Kisqali from you over the counter?

No, Kisqali requires a valid prescription from your doctor. We do not sell this product without a valid prescription.

Do you ship to the United States?

Yes, we do. It usually takes between 7 and 18 business days to receive your order from our pharmacy.

Is there a generic for Kisqali?

The generic alternative is currently unavailable (at this pharmacy).

Blog Post:

The Financial Burden of Cancer Medications; What the US Needs to Learn from Canada

Latest News:

Young women now have 'close to zero' risk of cervical cancer death after HPV jab (news published on June 18, 2026)

Similar Drugs in the category of Cancer Medications:

Arimidex Nolvadex Zofran Gleevec Femara

The information on this page is sourced from independent third parties contracted by CanadaPharmacyOnline. While we cannot guarantee its medical accuracy, we strongly recommend consulting a healthcare professional for personalized advice regarding medications or medical conditions.

Reviews From Real Customers